What Is Retatrutide?

Classification and structure

Retatrutide is a synthetic, lipidated peptide engineered for activity across three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and the glucagon receptor. An agonist is a molecule that activates a receptor.

In the scientific literature it is grouped with other incretin-mimetic peptides — for example the GLP-1 agonist semaglutide and the GIP/GLP-1 dual agonist tirzepatide — and is distinguished by the addition of glucagon-receptor activity.

Mechanism studied in research

Research into incretin biology characterises these receptors as follows:

• GLP-1 receptor — studied for its role in glucose-dependent insulin signalling.
• GIP receptor — an incretin receptor investigated in glucose and lipid metabolism.
• Glucagon receptor — studied in hepatic glucose output and energy metabolism.

Published research on triple agonism investigates how simultaneous activity at these receptors influences metabolic endpoints in study models.

These statements describe the published scientific record; they are not claims about any effect in humans.

Research background

Retatrutide has been evaluated in peer-reviewed preclinical and clinical research investigating metabolic endpoints, and as an investigational compound it remains the subject of ongoing study. Findings are reported in the primary scientific literature listed below.

Purity, testing and handling

Lazarus Labs supplies Retatrutide as a lyophilised (freeze-dried) reference material, independently tested to 99%+ purity, with a batch Certificate of Analysis (COA) available. Lyophilised peptides are typically stored cold and protected from light, in line with standard laboratory practice for reference materials.